Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) shares traded down 0.5% during mid-day trading on Wednesday . The stock traded as low as $26.80 and last traded at $26.80. 760 shares were traded during trading, an increase of 1,602% from the average session volume of 45 shares. The stock had previously closed at $26.93.
Analyst Ratings Changes
Separately, BNP Paribas initiated coverage on Hikma Pharmaceuticals in a report on Tuesday, May 13th. They set an "outperform" rating on the stock.
Read Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.28, a current ratio of 1.14 and a quick ratio of 0.65. The firm has a 50 day simple moving average of $27.68 and a 200-day simple moving average of $26.91.
About Hikma Pharmaceuticals
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Further Reading
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
